tiprankstipranks
Trending News
More News >

Rhythm Biosciences Secures NATA Accreditation, Paving Way for ColoSTAT® Launch

Story Highlights
Rhythm Biosciences Secures NATA Accreditation, Paving Way for ColoSTAT® Launch

Don’t Miss TipRanks’ Half-Year Sale

Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an update.

Rhythm Biosciences Ltd has successfully reinstated NATA accreditation for its geneType cancer risk assessment portfolio, following the acquisition of Genetype assets from Genetic Technologies Ltd. This milestone is pivotal for the company’s ColoSTAT® commercialisation strategy, allowing it to progress as an in-house in vitro diagnostic (IVD) and generate real-world data, essential for its global commercialization efforts.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple and affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes and reduce the global cancer burden by partnering with global entities for the commercialization and distribution of its solutions.

Average Trading Volume: 245,098

Technical Sentiment Signal: Sell

Current Market Cap: A$18M

Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1